CTRI/2023/11/059982尚未招募Unknown
A pilot two arm, two period, cross over, open label, Single-centre, comparative trial to Investigate the change in oral bioavailability of Nicotinamide Mononucleotide (NMN, 500mg) when 5mg Bioperine is added to NMN 500mg in normal healthy volunteers. - NI
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male subjects and/or non-pregnant, non-lactating female subjects of childbearing potential and/or female subjects who have attained menopause.
- •2. Subject of age 18 to 45 years and above with BMI of 18.50 – 30.0 Kg/m2.
- •3. Subjects with normal vital parameters Blood Pressure (120/80 to 139/89 mmHg), pulse rate (70-100 beats/min) and temperature (97.00F-99.00F) and general clinical examination or those considered not clinically significant as decided by the investigator.
- •4. Subject who agree not consume coffee, tea, cola, chocolate or any other xanthine containing food or drinks within 3 days prior to start of the study and during the washout period.
- •5. Subject with no current or recent (within 2 weeks before randomization) treatment with any another investigational product.
- •6. Negative pregnancy test for females and does not plan to become pregnant during course of the study
排除标准
- •1. History of uncontrolled systemic diseases such as cardiac, gastrointestinal, respiratory, hepatic, renal, endocrine, neurological, metabolic, psychiatric and hematological disorders, based on clinical investigator’s judgment.
- •2. History of chronic alcoholism/ chronic smoking/ drug of abuse.
- •3. Subjects with hypersensitivity to NMN and BIOPERINE or any of the excipients.
- •4. Pregnant or lactating female subjects.
- •5. History of consumption of tobacco containing products within 48 hours prior to the proposed time of dosing.
- •6. Subjects who are positive for hepatitis B, anti-hepatitis C and Human Immunodeficiency Virus (HIV 1&2).
- •7. Present or past history of intake of vitamins & mineral supplements, herbal medicines or any prescription drugs other than the drugs already included in patient’s treatment regimen or over the counter (OTC) medicines within 14 days which can potentially alter/interfere / modify the PK parameters of NMN and BIOPERINE or any other medication judged to be clinically significant by the investigator.
- •8. Subjects who had donated blood/had any other blood loss over 01 unit of blood during the last 01 months before study initiation.
研究者
相似试验
进行中（未招募）
不适用
OPEN PILOT STUDY, TWO ARMS, WITH HISTORIC CONTROL, MULTICENTRIC TO EVALUATE SAFETY AND EFFICACY OF ASSOCIATION WITH EVEROLIMUS AND LOW DOSES OF CYCLOSPORIN AND STEROIDS AFTER INDUCTION WITH MONOCLONAL ANTIBODY ANTI CD25 IN PEDIATRIC PATIENTS AFTER KIDNEY TRANSPLANTS - NDpediatric patient after kidney transplantMedDRA version: 9.1Level: LLTClassification code 10023439Term: Kidney transplant rejectionEUCTR2008-006729-15-ITISTITUTO GIANNINA GASLINI
招募中
不适用
A study of providing adult smokers, who smoke at least one cigarette per day, the opportunity to sample a range of nicotine replacement therapies (NRTs) in everyday non-medical community locations, to determine if this is acceptable to smokers, and whether it increases their motivation to quit smoking, encourages them to use NRTs, and helps them to quit smoking and remain abstinent for three months.Tobacco dependenceSmoking addictionMental Health - AddictionACTRN12614000054617Ministry of Health1,000
进行中（未招募）
不适用
A PILOT, RANDOMIZED, SINGLE SITE, 3 PARALLEL ARMS, OPEN-LABEL STUDY IN PATIENTS ON CHRONIC DIALYSIS WITH END STAGE RENAL DISEASE (ESRD) TO EVALUATE THE ENHANCING EFFECT OF TWO DOSES OF THYMOSIN ALPHA 1 ON THE IMMUNOGENICITY OF EGG-DERIVED H1N1sw MONOVALENT INFLUENZA VACCINE - NDZADAXIN ENHANCING EFFECT IN PATIENTS ON CHRONIC DIALYSIS WITH END STAGE RENAL DISEASE (ESRD) TREATED WITH EGG-DERIVED H1N1sw MONOVALENT INFLUENZA VACCINEMedDRA version: 12.1Level: LLTClassification code 10014647Term: End stage renal failureEUCTR2009-016362-85-ITSIGMA-TA
进行中（未招募）
1 期
STUDY TO ASSESS THE SHORT-TERM EFFECT OF THE ADMINISTRATION OF TOLVAPTAN AND OCTREOTIDE LAR COMPARED TO THE COMBINATION OF TOLVAPTAN AND PLACEBO IN PATIENTS AFFECTED BY ADPKD WITH NORMAL KIDNEY FUNCTION OR HYPERFILTRATIOAutosomal Dominant Policiytic Kidney DiseaseMedDRA version: 20.0 Level: LLT Classification code 10036046 Term: Polycystic kidney, autosomal dominant System Organ Class: 100000004850EUCTR2017-004701-40-ITIRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI20
尚未招募
4 期
A clinical saftey and efficacy trial of Sugarlite a marketeted product on Healthy lifestyle modificatioCTRI/2021/02/030921Zydus Wellness